Abstract: Provided is a fluorine-doped tin oxide support, a platinum catalyst for a fuel cell having the same, and a method for producing the same. Also described is a high electrical conductivity and electrochemical durability by doping fluorine to the tin oxide-based support through an electrospinning process. Thus, while resolving a degradation issue of the carbon support in the conventional commercially available platinum/carbon (Pt/C) catalyst, what is designed is to minimize an electrochemical elution of dopant or tin, which is a limitation of the tin oxide support itself and has excellent performance as a catalyst for a fuel cell.

Abstract: The present disclosure relates to optimised administration regimens of 5-HT1A agonists and levodopa in the management of movement disorders, such as Parkinson's disease and levodopa-induced dyskinesia (LID).

Abstract: The invention features a method of producing cells for transplantation into myocardial tissue of a mammal and a method for treating a disorder using the cells. The method comprises the steps: (a) providing bone marrow stem cells that have not been immortalized; (b) culturing said bone marrow stem cells in a culture medium containing IGF-1 (Insulin-like Growth Factor-I) under conditions that induce said cells to differentiate into cardiomyogenic cells; (c) monitoring the differentiation state of the cells of step (b); and (d) collecting the cells of step (b) when at least about 50% of said cells are cardiomyogenic cells. According to the method, the highest yield of the cells to be transplanted into mammal cardial tissue which have the characteristics of cardiomyocyte cell lineage mostly can be obtained. The cells produced as such can be used for treating a disorder characterized by insufficient cardiac function.